Back to Journals » Drug Design, Development and Therapy » Volume 13

Clinical And Bacteriological Impact Of Clarithromycin In Streptococcal Pharyngitis: Findings From A Meta-Analysis Of Clinical Trials

Authors Hoban DJ, Nauta J

Received 23 February 2019

Accepted for publication 11 September 2019

Published 16 October 2019 Volume 2019:13 Pages 3551—3558

DOI https://doi.org/10.2147/DDDT.S205820

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 2

Editor who approved publication: Dr Qiongyu Guo


Daryl J Hoban,1 Jos Nauta2

1Department of Medical Microbiology and Infectious Disease, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada; 2Department of Innovation & Development, Established Pharmaceuticals Division, Abbott Healthcare Products B.V., Weesp 1381 CP, The Netherlands

Correspondence: Jos Nauta
Department of Innovation & Development, Established Pharmaceuticals Division, Abbott Healthcare Products B.V., C.J. van Houtenlaan 36, Weesp 1381 CP, The Netherlands
Tel +31 294 47 7360
Email jos.nauta@abbott.com

Introduction: Among the bacterial upper respiratory tract infections (UTRIs), the most medically significant is pharyngitis due to Group A beta-hemolytic Streptococci (GABHS). A 2012 meta-review and a 2016 Cochrane systematic review reported favorably on the comparative efficacy and safety of clarithromycin in pediatric patients with URTIs and in adults with GABHS pharyngitis. In this paper, the evidence base for clarithromycin in patients with URTIs is augmented by a meta-analysis of comparative studies in GABHS pharyngitis.
Methods: A series of five outpatient trials of clarithromycin for the treatment of streptococcal pharyngitis from an internal database were subjected to meta-analysis. Active comparators comprised penicillin VK and erythromycin.
Results: Rates of clinical cure or improvement were very similar in all treatment assignments, but the rates of bacteriological cure were numerically higher with clarithromycin than with comparator antibiotics. Adverse events data indicated that clarithromycin was generally well tolerated in these studies, with a relatively low incidence of adverse events and few severe incidents.
Discussion: Though currently not advised as a first-line therapy for URTI in most guidelines, the results of the meta-analysis indicate that clarithromycin is nevertheless a valid, effective and largely well-tolerated treatment option for GABHS pharyngitis patients who cannot benefit from other agents.

Keywords: clarithromycin, erythromycin, amoxicillin, Streptococcus, pharyngitis, metaanalysis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]